Novo Nordisk is ceasing production of human insulin pens, focusing on newer obesity and diabetes injections. This shift has ...
Novo Nordisk said Thursday that it plans to eventually halt all of its human insulin pen production globally, ...
Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...
MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.
Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...
Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...
1 Day NVO 1.88% DJIA 0.68% S&P 500 -0.03% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
The sites will then by fully used by Novo Nordisk for filling its injection pens. Novo Holdings, Novo Nordisk and Catalent ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback